Significance of the NCI Molecular Analysis for Therapy Choice Program

The ODAC deemed the results from TALAPRO-2 are not sufficient to conclude a favorable benefit-risk profile for adding talazoparib to enzalutamide in non-HRRm mCRPC.

Xiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.

Manmeet Ahluwalia, MD, MBA, FASCO, discussed the importance of Brain Cancer Awareness Month for a community oncologist audience.

In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor (CAR) T-cell therapy.

In part 2, experts discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.